Project description
A new environmentally friendly way of producing drugs
Mechanochemistry is a pioneering, low-cost way of inducing chemical processes via mechanical stress. Potentially, it could be used to mitigate the considerable environmental impact of drug manufacturing because mechanochemistry is less energy-intensive, emits less CO2, and does not require chemical solvents. In a pilot scheme, the EU-funded IMPACTIVE project will develop mechanochemical processes to produce several active pharmaceutical ingredients used in drugs. If the concept is proven viable, drug manufacturing would then meet the new environmental stipulations imposed by the EU Green Deal. Results will be openly shared with pharmaceutical manufacturers and other interested parties to promote awareness and adoption of this potentially game-changing process.
Objective
The environmental impact of the pharmaceutical industry is a huge problem. The production and use of pharmaceuticals cause high CO2 emissions, contamination of soils, biota, and water, and even dangers to human health through carcinogenic impurities. Especially the use of solvents is a major problem. The European Green Deal has led to strict regulations on environmental pollution by the pharma industry, causing manufacturers to move outside of the EU due to the high costs associated with green pharma. This results in supply chain fragility and low crisis preparedness in Europe. New methods to produce pharmaceuticals in a green, efficient, and economically friendly way are required.
The IMPACTIVE project brings together the expertise and knowledge from two COST Actions and will develop novel green methods to produce active pharmaceutical ingredients (APIs) using mechanochemistry as a disruptive technology (as acknowledged by IUPAC). Mechanochemistry uses mechanical processes, such as ball milling, twin-screw extrusion, resonant acoustic mixing, and spray drying, to induce chemical reactions.
The advantages of mechanochemistry include: no solvent use, high efficiency, low costs, and reduced energy use and CO2 emission. Upon completion of the project, we will provide proof-of-concept at a small pilot scale of the use of mechanochemistry to produce 6 APIs from 3 different families of compounds. Based on a recent study, switching to mechanochemistry can reduce terrestrial ecotoxicity and CO2 emissions by more than 85%, while production costs were reduced with 12%. The results of the IMPACTIVE project will thus enable pharmaceutical manufacturers to move back to Europe while minimizing environmental pollution.Through our strong dissemination and communication strategy we will ensure that the project?s results are shared with scientists, the pharmaceutical industry, and stakeholders from regulatory and public authorities to achieve maximum impact.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesearth and related environmental sciencesenvironmental sciencespollution
- engineering and technologychemical engineeringchemical process engineering
- social scienceseconomics and businesseconomicssustainable economy
- natural scienceschemical sciences
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
34090 Montpellier
France
See on map
Participants (15)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
34296 Montpellier Cedex 5
See on map
6525 XZ Nijmegen
See on map
1348 Louvain La Neuve
See on map
12616 Tallinn
See on map
12205 Berlin
See on map
52062 Aachen
See on map
45470 Muelheim An Der Ruhr
See on map
D02 CX56 DUBLIN 2
See on map
32000 Haifa
See on map
50019 Firenze
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
09124 Cagliari
See on map
1000-043 Lisboa
See on map
2820 266 Charneca De Caparica
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
39012 Santander
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34090 Montpellier
See on map
Partners (4)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2800 Delemont
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
9470 Buchs
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4056 Basel
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Participation ended
EC4A 4AB London
See on map